Estrella Immunopharma Inc. Faces Nasdaq Delisting Threat Over Market Value Non-Compliance

Reuters
08/07
<a href="https://laohu8.com/S/ESLAW">Estrella Immunopharma Inc.</a> Faces Nasdaq Delisting Threat Over Market Value Non-Compliance

Estrella Immunopharma Inc. has announced that it received a notice from the Nasdaq Stock Market LLC on August 1, 2025, indicating non-compliance with Nasdaq Listing Rule 5550(b)(2). The company failed to maintain the required minimum Market Value of Listed Securities (MVLS) of $35 million for 30 consecutive business days, specifically from June 13 to July 31, 2025. While this notification does not immediately affect the company's listing, Estrella Immunopharma has been granted a 180-day period, until January 28, 2026, to meet the MVLS requirement by closing at or above $35 million for ten consecutive business days. The company is actively monitoring its MVLS and considering options to regain compliance, though there is no guarantee of success.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Estrella Immunopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-072746), on August 07, 2025, and is solely responsible for the information contained therein.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10